Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | NSD2 | O96028 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422738 | 0.83 | KDM4E (0.50) | MAPTALDH1A1KDM4ENSD2CYP1A2 | |
| SCHEMBL22946640 | 0.78 | KDM4E (0.61) | MAPTALDH1A1KDM4ENSD2CYP1A2 | |
| SCHEMBL1489105 | 0.78 | KDM4E (1.00) | MAPTALDH1A1KDM4ENSD2KIT | |
| SCHEMBL22946632 | 0.78 | KDM4E (0.61) | MAPTALDH1A1KDM4ENSD2CYP1A2 | |
| SCHEMBL420104 | 0.78 | MAPT (0.61) | MAPTALDH1A1KDM4ENSD2CYP1A2 | |
| SCHEMBL17794415 | 0.78 | MAPT (0.61) | MAPTALDH1A1KDM4ENSD2KIT | |
| SCHEMBL22737499 | 0.78 | KDM4E (0.61) | MAPTALDH1A1KDM4ENSD2KIT | |
| SCHEMBL25097119 | 0.78 | CYP1A2 (0.45) | MAPTALDH1A1KDM4ENSD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL30492354 | 0.76 | KDM4E (0.59) | MAPTALDH1A1KDM4ENSD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL8100733 | 0.76 | KDM4E (0.96) | MAPTALDH1A1KDM4ENSD2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024039858-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4306520-A1 | THIOPHENE COMPOUND AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2024-01-17 | — | — | EP | disclosed |
| EP-3628044-B1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4265608-A1 | BENZOHETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4215525-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-20090088406-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090088406-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090048292-A1 | SYNERGISTIC COMBINATION | BAYER SCHERING PHARMA AG (DE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009000558-A1 | SYNERGISTIC COMBINATION OF ANTHRANILAMIDE PYRIDINUREAS AND BENZAMIDE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-31 | — | — | WO | disclosed |
| US-7429592-B2 | Cyanoanthranilamide derivatives and the use thereof as medicaments | SCHERING AKTIENEGESELLSCHAFT (DE) | 2008-09-30 | — | — | US | disclosed |
| US-7429592-B2 | Cyanoanthranilamide derivatives and the use thereof as medicaments | SCHERING AKTIENEGESELLSCHAFT (DE) | 2008-09-30 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | MAPT 370/4885ALDH1A1 2458/4885KDM4E 2617/4885 |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | FLT4, KDR, FLT1 | MAPT 3356/4885ALDH1A1 2240/4885KDM4E 692/4885 |
| US-20090088406-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | MAPT 1263/4885ALDH1A1 345/4885KDM4E 1194/4885 |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, RUNX1, ACIN1 | MAPT 399/4885ALDH1A1 256/4885KDM4E 2880/4885 |
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM3, CHRM2 | MAPT 337/4885ALDH1A1 3389/4885KDM4E 2149/4885 |
| US-20090048292-A1 | SYNERGISTIC COMBINATION | HDAC1, HDAC2, HDAC11 | MAPT 2756/4885ALDH1A1 1235/4885KDM4E 1079/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | MAPT 2368/4885ALDH1A1 4026/4885KDM4E 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.